GlassScriptPhysician profile
Jose Meller
NPI 1629092259
$208,369.78
in general payments reported to CMS, 2019-2025
40 companies · $1,430 in 2025
The $1,430 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91K · 2020: $33K · 2021: $37K · 2022: $21K · 2023: $21K · 2024: $4,873 · 2025: $1,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $6,287 · Travel and Lodging: $948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,715.00 |
| Food and Beverage | $6,287.30 |
| Travel and Lodging | $947.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $57,687.19 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53,470.79 | 2019-2025 | Jardiance |
| Amgen INC. | $37,336.49 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $27,606.00 | 2020-2025 | Nexletol |
| Lilly USA, LLC | $14,717.87 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Daiichi Sankyo INC. | $7,000.00 | 2019-2021 | |
| Pfizer INC. | $2,732.68 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,398.75 | 2019-2025 | Eliquis, Camzyos |
| Novo Nordisk INC | $990.62 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Novartis Pharmaceuticals Corporation | $936.02 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $766.52 | 2019-2025 | Wainua, Farxiga, Lokelma |
| Merck Sharp & Dohme LLC | $492.81 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $470.03 | 2022-2025 | |
| Amarin Pharma, INC. | $459.82 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $455.04 | 2019-2023 | Livalo, Seglentis |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Meller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.